Theresa Agnew commences her role as CEO of BioGaia
BioGaia announces that Theresa Agnew begins her role today, 25 September 2023, as the Chief Executive Officer of BioGaia.
As previously communicated, Theresa Agnew has 20-years of experience in various leadership roles within consumer healthcare, over-the-counter (OTC) drugs, and medical devices from leading companies such as GlaxoSmithKline (GSK), Essilor, and Johnson & Johnson.
Chairman of the Board, Peter Rothschild, commented, "We are pleased to welcome Theresa to BioGaia. We are confident that she possesses the right competence to lead BioGaia's future growth journey as a Swedish world-leading probiotics company. Theresa's entry marks an exciting new phase for BioGaia in our ongoing transformation to becoming both a Business-to-Business company and a Business-to-Consumer company."
Read more about Theresa Agnew in our previous press release: https://www.biogaia.com/pressrelease/biogaia-appoints-theresa-agnew-as-new-ceo/.
Subscribe to BioGaia press releases here (https://www.biogaia.com/press/subscribe-to-press-releases/)
LinkedIn here (https://www.linkedin.com/company/biogaia-ab/)
BioGaia is an innovative Swedish healthcare company that develops, markets, and sells probiotic products with documented health benefits. The products are sold through local distribution partners or via own-distribution in over 100 markets. The class B share of the Parent Company BioGaia AB is quoted on the Mid Cap segment of Nasdaq Stockholm. biogaia.com (https://www.biogaia.com/)